Published in AIDS Weekly, June 28th, 2004
According to recent research from Germany, "In a controlled, prospective study, the efficacy of ritonavir 200 mg twice daily (bid) in inhibiting the decrease of amprenavir plasma concentrations caused by co-administration of lopinavir was assessed. Twelve HIV-seropositive patients were enrolled, and nine patients completed the 28-day study."
"At day 14," reported S. Mauss and coworkers, "plasma concentrations of amprenavir 600 mg bid and ritonavir 200 mg bid were determined over 12 hours. At day 15, lopinavir 400 mg bid was added. At day 28, plasma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.